ID Q8XMJ5_CLOPE Unreviewed; 1686 AA.
AC Q8XMJ5;
DT 01-MAR-2002, integrated into UniProtKB/TrEMBL.
DT 01-MAR-2002, sequence version 1.
DT 27-MAR-2024, entry version 127.
DE RecName: Full=Fibronectin type-III domain-containing protein {ECO:0000259|PROSITE:PS50853};
GN OrderedLocusNames=CPE0693 {ECO:0000313|EMBL:BAB80399.1};
OS Clostridium perfringens (strain 13 / Type A).
OC Bacteria; Bacillota; Clostridia; Eubacteriales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=195102 {ECO:0000313|EMBL:BAB80399.1, ECO:0000313|Proteomes:UP000000818};
RN [1] {ECO:0000313|EMBL:BAB80399.1, ECO:0000313|Proteomes:UP000000818}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=13 / Type A {ECO:0000313|Proteomes:UP000000818};
RX PubMed=11792842; DOI=10.1073/pnas.022493799;
RA Shimizu T., Ohtani K., Hirakawa H., Ohshima K., Yamashita A., Shiba T.,
RA Ogasawara N., Hattori M., Kuhara S., Hayashi H.;
RT "Complete genome sequence of Clostridium perfringens, an anaerobic flesh-
RT eater.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:996-1001(2002).
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; BA000016; BAB80399.1; -; Genomic_DNA.
DR RefSeq; WP_011009975.1; NC_003366.1.
DR STRING; 195102.gene:10489955; -.
DR CAZy; GH101; Glycoside Hydrolase Family 101.
DR KEGG; cpe:CPE0693; -.
DR HOGENOM; CLU_235534_0_0_9; -.
DR BRENDA; 3.2.1.97; 1503.
DR Proteomes; UP000000818; Chromosome.
DR GO; GO:0030246; F:carbohydrate binding; IEA:InterPro.
DR GO; GO:0033926; F:glycopeptide alpha-N-acetylgalactosaminidase activity; IEA:InterPro.
DR CDD; cd00063; FN3; 1.
DR CDD; cd14244; GH_101_like; 1.
DR Gene3D; 2.60.120.870; -; 1.
DR Gene3D; 2.60.40.1080; -; 1.
DR Gene3D; 2.70.98.10; -; 1.
DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 2.
DR Gene3D; 3.20.20.80; Glycosidases; 1.
DR Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR InterPro; IPR011081; Big_4.
DR InterPro; IPR013320; ConA-like_dom_sf.
DR InterPro; IPR025706; Endoa_GalNAc.
DR InterPro; IPR003961; FN3_dom.
DR InterPro; IPR036116; FN3_sf.
DR InterPro; IPR040633; Gal_mutarotas_3.
DR InterPro; IPR008979; Galactose-bd-like_sf.
DR InterPro; IPR014718; GH-type_carb-bd.
DR InterPro; IPR049314; GH101_dom-5.
DR InterPro; IPR040502; GH101_dom-6.
DR InterPro; IPR035364; Glyco_hyd_101_beta.
DR InterPro; IPR013783; Ig-like_fold.
DR Pfam; PF07532; Big_4; 1.
DR Pfam; PF00041; fn3; 1.
DR Pfam; PF18080; Gal_mutarotas_3; 1.
DR Pfam; PF17974; GalBD_like; 1.
DR Pfam; PF21466; GH101_dom-5; 1.
DR Pfam; PF17451; Glyco_hyd_101C; 1.
DR Pfam; PF12905; Glyco_hydro_101; 1.
DR SMART; SM00060; FN3; 2.
DR SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 1.
DR SUPFAM; SSF49265; Fibronectin type III; 1.
DR SUPFAM; SSF49785; Galactose-binding domain-like; 1.
DR PROSITE; PS50853; FN3; 1.
PE 4: Predicted;
KW Reference proteome {ECO:0000313|Proteomes:UP000000818};
KW Signal {ECO:0000256|SAM:SignalP}.
FT SIGNAL 1..29
FT /evidence="ECO:0000256|SAM:SignalP"
FT CHAIN 30..1686
FT /note="Fibronectin type-III domain-containing protein"
FT /evidence="ECO:0000256|SAM:SignalP"
FT /id="PRO_5004317946"
FT DOMAIN 1601..1686
FT /note="Fibronectin type-III"
FT /evidence="ECO:0000259|PROSITE:PS50853"
SQ SEQUENCE 1686 AA; 187828 MW; 00F276EBE357453B CRC64;
MGRKCMNKKI AAIIAAAVIV GQLPISVLAT PVNEAGDEIN SESAEILTNS DEEAEAYIQN
YDRPEGITWT KLAGSGSVEV TDGFLSVTNN GDYRIMEDQS PNIKNGELES KFTVGGSQTG
IIFRATESNY GMINYNSGTG WVIENKNSWE DITGPKLNNG DVVTVKATFV EKHLTVNVSV
NDGEFETIYD KESDLIPLQA GKVGYRGWGN AKTTKFDYIK YAPMTIDKGP IVSINEVNVE
TYPRVKPILP SSVTVNHENG MSSIKDVSWN YIPKESYSKP GTFKVEGTVE GTDVKAIANV
TVSSDLAYYE TNFETEETRG DWQVVQGGGS PSYEEGKVKI PMNGVSIAVD MNSPEVKNFT
YETDFSVDNN GGRIGLLFRY VSETEWGAVC YDNGSWVWKT GDGKYGNFPG TFTPEPGKTY
RIKLKVEDTN ITMWVDGEKI GQVAVSNLPD VRGKVGLTGW FGNKNVTLDN LVVEELGGIM
APEVGPLEEQ SIESDSMKVV LDNRFPTVIR YEWKGTEDVL SGASVDDLEA QYMVEINGEK
RIPKVTSEFA NNEGIYTLNF EDIGMTITLK MTVNENKLRM EVTDIQEGDV KLQTLNFPNH
SLASVSSLNN GKTASVLTTG DWNNINEEFT DVAKAKPGVK GKTYAFINDD KFAVTINNNT
IEGGNRVVLT TENDTLPDNT NYKKVGISNG TWTYKEILQD TTDQGSKLYQ GEKPWSEVII
ARDENEDGQV DWQDGAIQYR KNMKIPVGGE EIKNQMSYID FNIGYTQNPF LRSLDTIKKL
SNYTDGFGQL VLHKGYQGEG HDDSHPDYGG HIGMRQGGKE DFNTLIEQGK EYNAKIGVHI
NATEYTMDAF EYPTELVNEN APGWGWLDQA YYVNQRGDIT SGELFRRLDM LMEDAPELGW
IYVDVYTGNG WNAHQLGEKI NDYGIMIATE MNGPLEQHVP WTHWGGDPAY PNKGNASKIM
RFMKNDTQDS FLADPLVKGN KHLLSGGWGT RHDIEGAYGT EVFYNQVLPT KYLQHFQITK
MSENEVLFEN GVKAVRENSN INYYRNDRLV ATTPENSIGN TGIGDTQLFL PWNPVDEANS
EKIYHWNPLG TTSEWTLPEG WTSNDKVYLY ELSDLGRTLV KEVPVVDGKV NLEVKQDTPY
IVTKEKVEEK RIEDWGYGSE IADPGFDSQT FDKWNKESTA ENTDHITIEN ESVQKRLGND
VLKISGNEGA DAKISQSISG LEEGVTYSVS AWVKNDNNRE VTLGVNVGGK DFTNVITSGG
KVRQGEGVKY IDDTFVRMEV EFTVPKGVNS ADVYLKASEG DADSVVLVDD FRIWDHPGHT
NRDGYVFYED FENVDEGISP FYLSPGRGHS NRSHLAEKDI SIDANQRMNW VLDGRFSLKS
NQQPKEIGEM LTTDVSSFKL EPNKTYEFGF LYSLENAAPG YSVNIKNRDG EKIVSIPLEA
TGSNYAQDIF TKTKSVTHEF TTGDFAGDYY ITLEKGDGFK EVILDNIYVK EIDKSIESPE
LAHVNLNTVE HDLEVGQSVP FAINALMNNG ANVNLEEAEV EYKVSKPEVL TIENGMMTGA
SEGFTDVQVN ITVNGNKVSS NTVRVKVGNP EVEEEEVIVN PVRNFKVTDK TKKNVTVSWE
EPEKTYGLEG YVLYKDGKKV KEIGADKTEF TFKGLNRHTI YNFKIAAKYS NGELSTKESI
TVRTAR
//
